1 Hong KW, Oh B. Overview of personalized medicine

in the disease genomic era[J]. BMB Rep, 2010,

43:643-648.

2 Kalia M. Personalized oncology:Recent advances and

future challenges[J]. Metabolism, 2013, 62:S11-S14.

3 Abou-Chebl A. Management of acute ischemic

stroke[J]. Curr Cardiol Rep, 2013, 15:348.

4 Liu L, Wang D, Wong KS, et al. Stroke and stroke

care in China:huge burden, significant workload, and

a national priority[J]. Stroke, 2011, 42:3651-3654.

5 Saver JL, Fonarow GC, Smith EE, et al. Time to

treatment with intravenous tissue plasminogen

activator and outcome from acute ischemic stroke[J].

JAMA, 2013, 309:2480-2488.

6 Furlan AJ, Eyding D, Albers GW, et al. Dose

Escalation of Desmoteplase for Acute Ischemic Stroke

(DEDAS):evidence of safety and efficacy 3 to 9 hours

after stroke onset[J]. Stroke, 2006, 37:1227-1231.

7 Mandzia JL, Hill MD. Acute stroke management in

patients with known or suspected atrial fibrillation[J].

Can J Cardiol, 2013, 29:S45-S53.

8 Sandercock P, Wardlaw JM, Lindley RI, et al. The

benefits and harms of intravenous thrombolysis with

recombinant tissue plasminogen activator within 6

h of acute ischaemic stroke (the third international

stroke trial [IST-3]):a randomised controlled trial[J].

Lancet, 2012, 379:2352-2363.

9 Jauch EC, Saver JL, Adams HJ, et al. Guidelines for

the early management of patients with acute ischemic

stroke:a guideline for healthcare professionals from

the American Heart Association/American Stroke

Association[J]. Stroke, 2013, 44:870-947.

10 Chen C, Ye M, Chen BL, et al. Thrombolysis on

ischemic stroke patients with decreased level of

consciousness within 4.5 h[J]. CNS Neurosci Ther,

2013, 19:48-52.

11 中华医学会神经病学分会脑血管病学组急性缺血性

脑卒中诊治指南撰写组. 中国急性缺血性脑卒中诊治

指南2010[J]. 中华神经科杂志, 2010, 43:146-153.

12 中华医学会神经病学分会脑血管病学组缺血性脑卒

中二级预防指南撰写组. 中国缺血性脑卒中和短暂性

脑缺血发作二级预防指南2010[J]. 中华神经科杂志,

2010, 43:154-160.

13 Go r e l i ck PB, Fa r o o q MU. Ad va n c e s i n ou r

understanding of "resistance" to antiplatelet agents

for prevention of ischemic stroke[J]. Stroke Res Treat,

2013, 2013:727842.

14 Jia DM, Chen ZB, Zhang MJ, et al. CYP2C19

polymorphisms and antiplatelet effects of clopidogrel

in acute ischemic stroke in China[J]. Stroke, 2013,

44:1717-1719.

15 Lin YJ, Li JW, Zhang MJ, et al. The association

be twe en CYP2C19 genot y pe a nd of i n- s t ent

restenosis among patients with vertebral artery stent

treatment[J]. CNS Neurosci Ther, 2014, 20:125-130.

16 Shahpouri MM, Mousavi S, Khorvash F, et al.

Anticoagulant therapy for ischemic stroke:A review of

literature[J]. J Res Med Sci, 2012, 17:396-401.

17 Kirchhof P, Breithardt G, Aliot E, et al. Personalized

management of atrial fibrillation:Proceedings from

the fourth Atrial Fibrillation competence NETwork/

European Heart Rhythm Association consensus

conference[J]. Europace, 2013, 15:1540-1556.

18 Ross S, Pare G. Pharmacogenetics of antiplatelets and

anticoagulants:a report on clopidogrel, warfarin and

dabigatran[J]. Pharmacogenomics, 2013, 14:1565-1572.

19 Stone NJ, Robinson J, Lichtenstein AH, et al. 2013

ACC/AHA guideline on the Treatment of Blood

Cholesterol to Reduce Atherosclerotic Cardiovascular

Risk in Adults:a Report of the American College of

Cardiology/American Heart Association Task Force

on Practice Guidelines[J]. J Am Coll Cardiol, 2013,

pii:S0735-1097(13)06028-2.

20 Singhal AB, Biller J, Elkind MS, et al. Recognition

and management of stroke in young adults and

adolescents[J]. Neurology, 2013, 81:1089-1097.

21 Ji R, Schwamm LH, Pervez MA, et al. Ischemic

st roke and t ransient ischemic at tack in young

adults:risk factors, diagnostic yield, neuroimaging,

and thrombolysis[J]. JAMA Neurol, 2013, 70:51-57.